Angioedema of the Periorbital Region that Developed during Treatment with Etanercept in a Case of Refractory Adult-Onset Still's Disease

Angioedema of the Periorbital Region that Developed during Treatment with Etanercept in a Case of Refractory Adult-Onset Still's Disease

A 78-year-old Japanese man with adult-onset Still's disease that was refractory to conventional treatment, such as prednisolone (PSL) concomitant with methotrexate (MTX). Etanercept (50 mg/week) was added to PSL (12.5 mg/day) and MTX (12 mg/week). His manifestation improved dramatically, noneth...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine Vol. 51; no. 19; pp. 2801 - 2804
Main Authors: Kato, Takashi, Noguchi, Kei, Uehara, Masahiro, Nobuhara, Mamoru, Takahashi, Satoru, Kisamori, Yumi, Ikegaya, Hideki, Ogawa, Noriyoshi, Ohashi, Hiroyuki
Format: Journal Article
Language:English
Published: Japan The Japanese Society of Internal Medicine 01-01-2012
Subjects:
adult-onset Still's disease (AOSD)
adverse event
Aged
angioedema
Angioedema - diagnostic imaging
Angioedema - etiology
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Drug Hypersensitivity - diagnostic imaging
Drug Hypersensitivity - etiology
Etanercept
Humans
hypersensitivity
Immunoglobulin G - administration & dosage
Immunoglobulin G - adverse effects
Male
Methotrexate - administration & dosage
Orbital Diseases - diagnostic imaging
Orbital Diseases - etiology
Prednisolone - administration & dosage
Receptors, Tumor Necrosis Factor - administration & dosage
Still's Disease, Adult-Onset - complications
Still's Disease, Adult-Onset - drug therapy
Still's Disease, Adult-Onset - immunology
Tomography, X-Ray Computed
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 78-year-old Japanese man with adult-onset Still's disease that was refractory to conventional treatment, such as prednisolone (PSL) concomitant with methotrexate (MTX). Etanercept (50 mg/week) was added to PSL (12.5 mg/day) and MTX (12 mg/week). His manifestation improved dramatically, nonetheless massive edema of the periorbital region developed by the fourth injection, which kept his palpebral fissure completely closed. There was also a marked injection site reaction to etanercept. A diagnosis of angioedema due to etanercept was thus made, and the drug was discontinued. His angioedema began to ameliorate soon after antihistamines were introduced without any critical involvement, such as laryngeal obstruction.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.51.8243